Dr. Mark E. Robson, MD

Dr. Robson practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Robson's NPI, 1770554511, was assigned on January 30, 2006. Dr. Robson graduated from UVA School of Medicine in 1986. Dr. Robson holds New York license 203117.

Dr. Robson's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Robson's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Robson to 6 more group practices and clinics and 5 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Robson practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Robson's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Robson is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Robson's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists breast cancer among the conditions Dr. Robson treats.

CMS data shows 286 Medicare services from Dr. Robson across 6 procedure codes in 2024, for 137 Medicare patients. Medicare paid $21,660 for them. Every service was in an office.

CMS counts 137 Medicare patients who saw Dr. Robson in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have cancer, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Robson's median patient age at 67, with 96% women.

In 2024, Dr. Robson wrote 184 Medicare Part D claims for 55 patients. 78% of them were for generic drugs. CMS names the drug for 122 of them, across 5 drugs with 11 or more claims each, at $310,309 in total drug cost. In 2023, CMS named 48 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Robson for performance year 2024, reported as part of a group. Dr. Robson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Robson as offering telehealth.

Dmand AI links 406 papers to Dr. Robson, published from 2002 to 2025. 2019 was the busiest year, with 41. The most frequent topics are Breast Neoplasms, Genetic Predisposition to Disease and Germ-Line Mutation. Dr. Robson has published most often in J Clin Oncol. Dr. Robson's most frequent co-authors are Kenneth Offit, MD, Zsofia K. Stadler, MD and Susan M. Domchek, MD.

Dmand AI links Dr. Robson to 9 clinical trials. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Fanconi Anemia, Complementation Group D1. Memorial Sloan Kettering Cancer Center sponsors the most, 8.

CMS Open Payments shows 57 general payments to Dr. Robson from 4 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 38% of the total. AstraZeneca Pharmaceuticals LP paid the most, $46,881. It also lists 8 research payments totaling $10,548 from 2021 to 2025.

Dr. Robson graduated from UVA School of Medicine in 1986. Dr. Robson is a member of ASCO.

Dr. Robson is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.